Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Prelude Therapeutics Inc reported that director Katina Dorton received a grant of stock options covering 38,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Dorton continues providing service to the company through the vesting date. Following this grant, she holds options for 38,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dorton Katina
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 38,000 | $0.00 | -- |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 38,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 38,000 options
Exercise price: $3.94 per share
Expiration date: June 8, 2036
+2 more
5 metrics
Option grant size
38,000 options
Director stock option award to Katina Dorton
Exercise price
$3.94 per share
Strike price for director stock options
Expiration date
June 8, 2036
Option term end for director grant
Shares underlying options
38,000 shares
Common stock underlying the director options
Post-grant derivative holdings
38,000 options
Total options held directly after transaction
Key Terms
Director Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more
5 terms
Director Stock Option (Right to Buy) financial
"security_title: "Director Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "3.9400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vesting financial
"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Prelude Therapeutics (PRLD) disclose in this Form 4 for Katina Dorton?
Prelude Therapeutics reported a director stock option grant to Katina Dorton. She received options for 38,000 common shares as compensation, with vesting tied to continued service and no open-market share purchases or sales reported.
How many Prelude Therapeutics (PRLD) options were granted to director Katina Dorton?
Katina Dorton was granted options covering 38,000 shares of Prelude Therapeutics common stock. These options give her the right to buy shares at a fixed exercise price if and when they vest and she chooses to exercise.
What is the exercise price and expiration date of Katina Dorton’s PRLD options?
The granted options have an exercise price of $3.94 per share and an expiration date of June 8, 2036. This means she can buy shares at $3.94 any time after vesting and before that expiration date, subject to plan terms.
When do Katina Dorton’s Prelude Therapeutics (PRLD) options vest?
The options will fully vest on the earlier of Prelude’s next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditioned on Katina Dorton continuing to provide service to the company on each applicable vesting date.
How many Prelude Therapeutics (PRLD) options does Katina Dorton hold after this grant?
After this reported transaction, Katina Dorton holds options for 38,000 shares of Prelude Therapeutics common stock directly. This filing does not show additional derivative positions beyond this new award in the derivative summary.